Business
COLLABORATION WITH IMPERIAL COLLEGE LONDON
COLLABORATION WITH IMPERIAL COLLEGE LONDON.
About this update from Immupharma Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7976T\n Immupharma PLC\n 29 November 2021\n \n \n \n \n \n \n \n \n \n RNS | 29 NOVEMBER 2021\n ImmuPharma PLC\n (\"ImmuPharma\" or the \"Company\")\n \n COLLABORATION WITH IMPERIAL COLLEGE LONDON \n \n \n ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company,\n is very pleased to announce that it has signed a 2-year collaboration agreement with Imperial College London.\n \n Under the collaboration, Imperial College will provide significant intellectual input and guidance on a number of innovative peptide assets being developed at our R&D subsidiary, ImmuPharma Biotech in Bordeaux.\n \n \n Dr Tim Franklin, Chief Operating Officer of ImmuPharma, added: \"We are allextremely excited to be working with such a world leading academic institute. This union will be invaluable in guiding and progressing our earlier stage product development portfolio, as well as enhancing our intellectual property base.\"\n \n \n Dr Sébastien Goudreau, Chief Executive Officer of ImmuPharma Biotech, added: \"We are delighted that now with the full support from the new Board for our innovative research programs, we have the opportunity of working with collaboration partners which include world leading academic institutes such as Imperial College London.\"\n \n \n \n \n End\n \n \n \n \n \n \n \n \n This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n \n \n \n \n \n For further information please contact: ImmuPharma PLC (www.immupharma.com)Tim McCarthy, Chairman and Chief Executive Officer+ 44 (0) 207 152 4080Dr Tim Franklin, Chief Operating Officer Lisa Baderoon, Head of Investor Relations & Non-Executive Director+ 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD)Neil Baldwin Stanford Capital Partners (Joint Broker)Patrick ClaridgeJohn HowesBob Pountney SI Capital (Joint Broker)Nick Emerson +44 (0) 203 368 3550 +44 (0) 20 3650 3650 +44 (0) 148...